These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 16432265

  • 1. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
    Karim A, Tolbert D, Cao C.
    J Clin Pharmacol; 2006 Feb; 46(2):140-8. PubMed ID: 16432265
    [Abstract] [Full Text] [Related]

  • 2. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW, Suess PE, Griffiths RR.
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [Abstract] [Full Text] [Related]

  • 3. Ramelteon: a review of its therapeutic potential in sleep disorders.
    Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP.
    Adv Ther; 2009 Jun; 26(6):613-26. PubMed ID: 19568703
    [Abstract] [Full Text] [Related]

  • 4. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
    Erman M, Seiden D, Zammit G, Sainati S, Zhang J.
    Sleep Med; 2006 Jan; 7(1):17-24. PubMed ID: 16309958
    [Abstract] [Full Text] [Related]

  • 5. Ramelteon for the treatment of insomnia.
    Borja NL, Daniel KL.
    Clin Ther; 2006 Oct; 28(10):1540-55. PubMed ID: 17157111
    [Abstract] [Full Text] [Related]

  • 6. The effects of ramelteon in a first-night model of transient insomnia.
    Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J.
    Sleep Med; 2009 Jan; 10(1):55-9. PubMed ID: 18691937
    [Abstract] [Full Text] [Related]

  • 7. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
    Mini LJ, Wang-Weigand S, Zhang J.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
    [Abstract] [Full Text] [Related]

  • 8. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P.
    Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
    [Abstract] [Full Text] [Related]

  • 9. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
    Richardson G, Wang-Weigand S.
    Hum Psychopharmacol; 2009 Mar; 24(2):103-11. PubMed ID: 19090503
    [Abstract] [Full Text] [Related]

  • 10. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M.
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [Abstract] [Full Text] [Related]

  • 11. Ramelteon: a novel treatment for the treatment of insomnia.
    Wurtman R.
    Expert Rev Neurother; 2006 Jul; 6(7):957-64. PubMed ID: 16831111
    [Abstract] [Full Text] [Related]

  • 12. Ramelteon: a novel approach in the treatment of insomnia.
    Reynoldson JN, Elliott E, Nelson LA.
    Ann Pharmacother; 2008 Sep; 42(9):1262-71. PubMed ID: 18648020
    [Abstract] [Full Text] [Related]

  • 13. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.
    Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP.
    Nat Clin Pract Neurol; 2007 Apr; 3(4):221-8. PubMed ID: 17410109
    [Abstract] [Full Text] [Related]

  • 14. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T, Stubbs C, Walsh JK.
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [Abstract] [Full Text] [Related]

  • 15. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
    Wang-Weigand S, Watissée M, Roth T.
    Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
    [Abstract] [Full Text] [Related]

  • 16. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.
    Greenblatt DJ, Harmatz JS, Karim A.
    J Clin Pharmacol; 2007 Apr; 47(4):485-96. PubMed ID: 17389558
    [Abstract] [Full Text] [Related]

  • 17. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.
    Roth T, Seiden D, Wang-Weigand S, Zhang J.
    Curr Med Res Opin; 2007 May; 23(5):1005-14. PubMed ID: 17519067
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and clinical safety of ramelteon: an evidence-based review.
    Sateia MJ, Kirby-Long P, Taylor JL.
    Sleep Med Rev; 2008 Aug; 12(4):319-32. PubMed ID: 18603221
    [Abstract] [Full Text] [Related]

  • 19. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel.
    Zee PC, Wang-Weigand S, Wright KP, Peng X, Roth T.
    Sleep Med; 2010 Jun; 11(6):525-33. PubMed ID: 20483660
    [Abstract] [Full Text] [Related]

  • 20. Ramelteon: application withdrawn. Ramelteon in insomnia: withdrawal of marketing application in patients' best interests.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19639675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.